Li Guiling, Cheng Mingxia, Hong Kai, Jiang Yao
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Onco Targets Ther. 2023 Mar 6;16:157-163. doi: 10.2147/OTT.S400376. eCollection 2023.
Metastatic cervical cancer has a poor prognosis, and treatment options are limited. Immunotherapy has been used to achieve disease control in patients with cervical cancer; however, the efficacy of immunotherapy retreatment after disease progression is unclear. This study aimed to explore the efficacy and safety of immunotherapy retreatment in metastatic cervical cancer.
We retrospectively reviewed the clinical data of patients with metastatic cervical cancer who underwent immunotherapy retreatment after disease progression following previous immunotherapy from June 2019 to April 2021.
Fifteen patients were included in this study. All patients received combination immunotherapy retreatment consisting of camrelizumab, nab-paclitaxel, and apatinib. Four (26.7%) patients achieved partial response while three (20.0%) achieved stable disease. The objective response rate and disease control rate were 26.7% and 46.7%, respectively. The median progression-free survival and overall survival were 3.0 (95% confidence interval: 1.0-5.0) and 8.0 (95% confidence interval: 3.4-12.6) months, respectively. None of the patients discontinued treatment because of intolerable toxicity.
Our findings suggest that the triplet combination immunotherapy retreatment could be a therapeutic option for patients with metastatic cervical cancer who failed initial immunotherapy.
转移性宫颈癌预后较差，治疗选择有限。免疫疗法已用于实现宫颈癌患者的疾病控制；然而，疾病进展后免疫疗法再治疗的疗效尚不清楚。本研究旨在探讨免疫疗法再治疗转移性宫颈癌的疗效和安全性。
我们回顾性分析了2019年6月至2021年4月期间接受过免疫治疗且疾病进展后接受免疫疗法再治疗的转移性宫颈癌患者的临床资料。
本研究纳入了15例患者。所有患者均接受了由卡瑞利珠单抗、白蛋白结合型紫杉醇和阿帕替尼组成的联合免疫疗法再治疗。4例（26.7%）患者达到部分缓解，3例（20.0%）患者病情稳定。客观缓解率和疾病控制率分别为26.7%和46.7%。无进展生存期和总生存期的中位数分别为3.0（95%置信区间：1.0 - 5.0）个月和8.0（95%置信区间：3.4 - 12.6）个月。没有患者因无法耐受的毒性而停止治疗。
我们的研究结果表明，三联联合免疫疗法再治疗可能是初始免疫治疗失败的转移性宫颈癌患者的一种治疗选择。
